Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Achieving better response rates in metastatic RCC

Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA speaks at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, hoping that data emerging from TKI/immunotherapy combination trials can improve responses in metastatic renal cell carcinoma (RCC). Dr McGregor is excited about the ongoing trials investigating TKI and immunotherapy combinations, such as the pembrolizumab and axitinib, and highlights the considerations that need to be made in achieving better response rates in metastatic RCC patients.